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Celiac disease (CD) is an autoimmune disorder caused by a permanent sensitivity to gluten in genetically
susceptible individuals. Accurate diagnosis of CD at an early stage and its treatment with a gluten-free
diet (GFD) are important for optimum treatment and prognosis. Recently, by employing a noninvasive
metabonomic approach, we have shown that CD has a well-defined metabonomic signature. Here we
address potential CD patients, defined as subjects who do not have, and have never had, a jejunal
biopsy consistent with clear CD, and yet have immunological abnormalities similar to those found in
celiac patients. Sixty-one overt CD patients at diagnosis, 29 patients with potential CD, and 51 control
subjects were examined by 1H NMR of their serum and urine: out of 29 potential CD patients, 24 were
classified as CD and 5 as control subjects. Potential CD largely shares the metabonomic signature of
overt CD. Most metabolites found to be significantly different between control and CD subjects were
also altered in potential CD. Our results demonstrate that metabolic alterations may precede the
development of small intestinal villous atrophy and provide a further rationale for early institution of
GFD in patients with potential CD, as recently suggested by prospective clinical studies.
Keywords: Potential Celiac Disease • Metabolomics • Metabonomics • Nuclear Magnetic Resonance
Introduction
Celiac disease (CD) is a common autoimmune disorder
triggered by the ingestion of gluten and related prolamins, plant
storage proteins found in wheat, barley, and rye, in genetically
susceptible individuals.1 Patients display various degree of
intestinal inflammation, ranging from mere increase in the
number of intraepithelial lymphocytes (lymphocytic enteritis)
to elongation of crypts (crypt hyperplasia), severe mononuclear
cell infiltration of the lamina propria and overt villous atrophy.
Accordingly, clinical manifestations range from completely
asymptomatic forms (so-called silent CD patients) to symptoms
and signs of global malabsorption.
In the majority of cases, a gluten-free diet (GFD) leads to
disappearance of clinical symptoms, recovery of normal mu-
cosal histology, disappearance of the serological signs, and the
prevention of complications, while reintroduction of gluten into
the diet, at any stage, causes reactivation of the disease.2-7
Small-bowel mucosal villous atrophy has traditionally been
considered the conditio sine qua non for diagnosing CD.8 As a
logical consequence, although there is a general consensus on
dietary treatment for symptomatic subjects with enteropathy,
it is not so for potential cases (i.e., patients with positive CD-
associated serology, but no enteropathy).9 However, accumu-
lating evidence suggests that celiac patients may suffer from
gluten-sensitive symptoms even before villous atrophy has
developed,10-13 and an increased risk of osteoporosis has been
reported also for this group of patients.10
In a recent work, Bertini et al. have examined a cohort of
CD patients, before and after gluten free diet GDF, and healthy
controls, by 1H NMR metabolic profiling of their serum and
urine samples.14 Through multivariate analysis, they were able
to demonstrate the existence of a clear metabonomic15 signa-
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ture of CD and to identify a number of serum and urine
metabolites whose levels were significantly different in CD at
diagnosis as compared to controls. The metabonomic signature
as well the levels of most metabolites reverted to normal within
12 months of a strict GFD. The metabonomic fingerprint of
CD has two components not directly linked to malabsorption:
one related to energy metabolism, and the other related to
alterations of gut microflora. Using this metabolic fingerprint,
it is possible to make predictions about the CD status wit
reasonably good accuracy (about 84%).
These results, although extremely encouraging, are not
particularly helpful from a merely diagnostic point of view,
since serology by blood test already achieves a sensitivity of
about 98% and a specificity of over 95%.16 Moreover, profes-
sional guidelines recommend that a positive blood test should
still be followed by an endoscopy, and this would pick up false
positives as well as offer alternative explanations for the
symptoms.17-19 However, the clear discrimination between
patients and healthy subjects and patients and follow-up cases,
achieved by metabolic fingerprinting, undoubtedly demon-
strates the existence of a metabolic signature for CD both in
serum and urine.
Under the inclusive definition of celiac disease, or gluten-
sensitive enteropathy, the concepts of silent, latent, and
potential CD have been introduced over 15 years ago by
Professor Anne Ferguson.20 While silent CD is marked by severe
damage to the jejunal mucosa in the absence of clinical
symptoms, both latent and potential CD are characterized by
jejunal mucosa that would be reported as normal by most
clinical pathologists in an individual on a gluten-containing
diet. Latent subjects sometimes in their life have had a flat
jejunal biopsy which recovered on a gluten-free diet. Latent
CD patients are often symptomatic; neither high titers of gliadin
antibodies nor mucosal changes (including raised intraepithe-
lial lymphocyte counts) are obligate features of latent CD,
although the presence of elevated anti-endomysial antibodies
(EmA) is probably the best predictor of progression toward
villous atrophy.21
The term potential CD has been proposed for those subjects
who, as opposed to latent CD patients, do not have, and have
never had, a jejunal biopsy consistent with clear CD, and yet
have immunological abnormalities similar to those found in
celiac patients. Good markers of potential CD include the
presence of serum endomysial antibodies, a high count of
intraepithelial lymphocytes, and subtle pathological alteration
such as increased density of intraepithelial lymphocytes ex-
pressing gamma delta T cell receptor, signs of activated
mucosal cell-mediated immunity, celiac-like intestinal antibody
pattern, and positive rectal gluten challenge.21
Our interest in potential CD subjects stems from the fact
that they have all the typical immunoclinical features of clear
CD, in the absence of any apparent intestinal damage. The aim
of this work is to investigate whether (and to what extent)
potential CD patients share the same metabolic fingerprint of
overt CD patients, thereby addressing an as yet open question:
are the metabolic alterations associated to CD due to malab-
sorption (i.e., intestinal damage) or are they independent of
mucosal injury and therefore intrinsic to the pathology? In
other words, our aim is to clarify if we are effectively looking
at a metabolic signature of CD or if we are simply following
the metabolic modification due to intestinal malabsorption. To
this end, a suitable cohort of potential CD subjects is ideal
because, by definition, they do not have villous atrophy.
Recent prospective studies on both adults and children
classified as potential CD patients have addressed the question
of whether GFD prevents development of villous atrophy and/
or alleviates the symptoms. There is increasing evidence that
GFD has a beneficial effect, although the effect can be more22,23
or less24 marked. The comparison of the fingerprint of potential
CD subjects with overt CD subjects and healthy controls can
thus contribute to the open debate about whether or not it is
necessary to put these patients on a GFD.
Materials and Methods
Volunteers Recruitment and Samples Collection. The vol-
unteers participating in this study were recruited by the
Tuscany Referral Center for Adult CD. In total, 141 adult (35
males, 106 females, mean age 38.3 ( 13.9 years) participated
in this study. Among the celiac group, 61 patients (10 males,
51 females, mean age 39.8 ( 13.9 years) were affected by overt
CD, and 29 were diagnosed as having potential CD (6 males,
23 females, mean age 34.4 ( 14.3 years). The diagnosis of CD
was based on positive serology and confirmed by histological
examination of small bowel biopsies taken from the distal part
of the duodenum. Small intestinal mucosal damage was
graduated according to the classification of Marsh modified
by Oberhuber.25 According to the hystology, 7 patients with
overt CD had partial villous atrophy (Marsh 3A), 7 subtotal
villous atrophy (Marsh 3B), and 16 total villous atrophy (Marsh
3C). Patients with potential CD were all positive for anti-tissue
transglutaminase antibodies (tTGA); all but one were also EmA
positive; histological examination revealed an apparently nor-
mal mucosa (Marsh 0) in 9 subjects, just an increase in
intraepithelial lymphocytes (Marsh 1) in 12 and increased
intraepithelial lymphocytes coupled with crypt hyperplasia
(Marsh 2) in 8 patients. The control group consisted of 51
nonceliac subjects (19 males, 32 females, mean age 36.6 ( 14.2
years): 34 (13 males, 21 females, mean age 37.6 ( 14.8 years)
were healthy controls from the medical staff of the Gastrointes-
tinal Unit and 17 (6 males, 11 females, mean age 30.9 ( 12.5
years) were patients with clinical suspicion of celiac disease;
they were all EmA and tTGA negative. Therefore, for ethical
reasons, the 34 controls that were from the medical staff did
not undergo intestinal biopsy; in the remaining 17 cases,
gastrointestinal endoscopy was performed only when it was
considered necessary to the diagnosis. The clinical character-
istics of all the subjects, including those examined in the
previous work14 are reported in Supporting Table S1.
Each subject had fasted overnight, and urine and blood were
collected in the morning preprandial. Venous blood samples
were collected into plastic serum tubes (6 mL), with increased
silica act clot activator, silicone-coated interior (Becton
Dickinson, Plymouth, U.K.). Samples were allowed to clot by
standing tubes vertically at room temperature (22 °C) for 60
min. Tubes were centrifuged at 1800 RCF for 10 min at room
temperature. Within 15 min of centrifugation, the supernatant
(serum) was transferred in 500 µL aliquots to prelabeled 1 mL
cryovials (Bruker BioSpin, Milan, Italy). Three aliquots per
patient were immediately frozen and stored at -80 °C until
used.
First morning preprandial urine void was used for the
collection period. Patients were supplied with appropriate
collection instructions and information on fasting, diet and
medication restrictions when necessary. The urine samples
were collected into prelabeled sterile collections cups. One
milliliter of urine samples was transferred into prelabeled 1 mL
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sterile cryovials (Nalgene, Rochester, NY). Three aliquots per
patient were immediately frozen and stored at -80 °C until
used.
Additionally, CD patients and healthy controls were asked
to record their dietary intake and the use of any medication
(either prescribed or self-administered) on the day before each
visit, and to fast from midnight until blood samples and urine
were collected the following morning.
Genotyping. Potential CD patients were analyzed for CD-
related genes following the procedure already reported.14 They
were all genetically susceptible: in particular 22 were DQ2, 3
DQ8, and 4 DQ2.2 positive (i.e., they carried the HLA genes
DRB1 *07, DQB1 *0202 and DQA1 *0201, see Supporting Table
S2). In the course of our previous work,14 we had checked that
among healthy subjects those who were DQ2/DQ8 positive
were not statistically distinguishable from the negative ones,
while they were distinguishable from the CD patients.
Antibody Testing. Anti-tissue transglutaminase antibodies
were measured by a commercially available enzyme-linked
immunosorbent assay kit (EutTG, Eurospital, Trieste, Italy) that
employs human recombinant tTG as antigen; EmA were
determined by indirect immunofluorescence, using tissue
section of monkey esophagus (Eurospital), as previously de-
scribed.26
Citrulline Assay. Labeled standards of citrulline were pur-
chased from Cambridge Isotope Laboratories, Andover, MA; a
stock solution was made in methanol. The standard concentra-
tion was 500 µmol/L. To obtain working solutions, daily
dilutions (1:100) were made using methanol-water 85:15. All
chemicals and solvents were of the highest purity available from
commercial sources and were used without any further
purification.
A dried serum spot was punched into a 1.5 mL tube or a 96
well plate and 200 µL of methanol containing labeled standard
was added. The sample was shaken on a vortex system for 20
min, and was then dried under a nitrogen flow at 50 °C. The
extracted amino acid was derivatized to butyl-ester using
n-butanol and HCl (3 M) at 65 °C for 25 min. After derivatiza-
tion, the sample was dried under nitrogen flow at 55 °C and
then recovered using 200 µL of water/acetonitrile (1:1) contain-
ing 0.1% formic acid. A total of 40 µL of the diluted sample
was injected in FIA (Flow Injection Analysis) mode for the
MS/MS experiments.
An Applied Biosystems-Sciex (Toronto, Canada) API 4000
triple-quadrupole mass spectrometer equipped with a Tur-
boIonSpray source was employed for this study. The TurboIon-
Spray source was operated in positive ion mode with a needle
potential of +5900 V and with a “turbo” gas flow of 10 L/min
of air heated at 400 °C (nominal heating-gun temperature).
Mass calibration and resolution adjustments on the resolving
quadrupoles were performed automatically by using a PPG 10-7
mol/L solution introduced via the built-in infusion pump. The
peak width was set on both resolving quadrupoles at 0.7 Th
(measured at 1/2 height) for all MS and MS/MS experiments.
Collision Activated Dissociation (CAD) MS/MS was performed
in the LINAC Q2 collision cell, operating with 10 mTorr pressure
of nitrogen as collision gas. The declustering potential (DP) and
collision energy (CE) were automatically optimized for amino
acids using the Analyst 1.3.2 software. The resulting DP was
+20 eV, and optimal CE was found to be 25 eV.
MS and MS/MS spectra were collected in continuous flow
mode by connecting the infusion pump directly to the Tur-
boIonSpray source. The quantitation experiments were per-
formed using a Series 1100 Agilent Technologies (Waldbronn,
Germany) CapPump coupled to an Agilent Micro ALS au-
tosampler, both fully controlled from the API 4000 data system.
Experimental flow rate was 50 µL/min using water/acetonitrile
(1:1) mixture containing 0.1% formic acid. The eluent from the
column was directed to the TurboIonSpray probe. The acquired
data were processed using the Analyst 1.4.1 proprietary software
including the “Explore” option (for chromatographic and
spectral interpretation) and the ChemoView software (for
quantitative information generation).
NMR Sample Preparation. Frozen serum samples were
thawed at room temperature and shaken before use. A total of
300 µL of a phosphate sodium buffer (70 mM Na2HPO4; 20%
(v/v) 2H2O; 0.025% (w/v) NaN3; 0.8% (w/v) sodium trimethylsilyl
[2,2,3,3-2H4]propionate (TSP); pH 7.4) was added to 300 µL of
each serum sample, and the mixture was homogenized by
vortexing for 30 s. A total of 550 µL of this mixture was
transferred into a 4.25 mm NMR tube (Bruker BioSpin srl) for
analysis.
Frozen urine samples were thawed at room temperature and
shaken before use. Samples were centrifuged at 1.4 × 104g for
5 min and 540 µL of the supernatant was added to 60 µL of
sodium phosphate buffer (0.2 M Na2HPO4; 0.2 M NaH2PO4 in
100% 2H2O; pH 7.0) also containing 10 mM TSP, and 30 mM
NaN3. A total of 450 µL of the mixture was pipetted into 4.25
mm NMR tubes (Bruker BioSpin srl).
NMR Analysis. 1H NMR spectra for all samples were acquired
using a Bruker 600 MHz spectrometer (Bruker BioSpin) operat-
ing at 600.13 MHz proton Larmor frequency and equipped with
a 5 mm CPTCI 1H-13C/31P-2H cryo-probe including a z-axis
gradient coil, an automatic tuning-matching (ATM) and an
automatic sample changer. A PT 100 thermocouple provided
temperature stabilization at the level of approximately 0.1 K
for the sample. Before measurement, samples were kept for at
least 3 min inside the NMR probehead, for temperature
equilibration (300 K).
For each urine sample, a one-dimensional NMR spectrum
was acquired with water peak suppression using a standard
pulse sequence (NOESYpresat; Bruker), using 64 free induction
decays (FIDs), 64k data points, a spectral width of 12 019 Hz,
an acquisition time of 2.7 s, a relaxation delay of 4 s, and a
mixing time of 100 ms.
One-dimensional spectra of serum samples were acquired
using a Carr-Purcell-Meiboom-Gill (CPMG; Bruker)
spin-echo sequence to suppress signals arising from high
molecular weight molecules and a standard pulse sequence
(NOESYpresat, same acquisition parameters as in the case of
urine samples).
Spectral Processing. Free induction decays were multiplied
by an exponential function equivalent to a 1.0 Hz line-
broadening factor before applying Fourier transform. Trans-
formed spectra were manually corrected for phase and baseline
distortions and calibrated (TMSP peak at 0.00 ppm) using
TopSpin (Version 2.1, Bruker). Each 1-D spectrum in the range
between 0.02 and 10.00 ppm was segmented into 0.02-ppm
chemical shift bins, and the corresponding spectral areas were
integrated using AMIX software (Bruker BioSpin). Regions
between 6.0 and 4.5 ppm containing residual water and urea
signals were removed. The total spectral area was calculated
on the remaining bins and normalization was carried out on
the data prior to pattern recognition.
Statistical Analysis. Data reduction was obtained by means
of Kernel Orthogonal Projection to Latent Structure (KOPLS),27
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using the algorithm implemented in the R-library “kopls”28
using a Gaussian kernel.
For the purpose of classification, we used the Support Vector
Machines (SVM) method29 applied on the KOPLS scores. The
“libsvm” module (LIBSVM: a Library for Support Vector Ma-
chines) of the R-library “e1071” was used.30
The statistical procedure used is a combination of KOPLS
for data reduction (i.e., to reduce the initial number of variables
and to have a clear depiction of the class separation) followed
by SVM on the KOPLS scores. SVM are used with the default
“C-classification” settings.
Accuracy, specificity, and sensitivity were estimated using
standard definitions. The global accuracy for classification was
assessed by means of double cross-validation scheme.31 The
original data set was spit in a training set (90%) and a test set
(10%) prior to any other step of statistical analysis. Parameter
selection was carried out by 3-fold cross-validation on the 90%
training set. The whole procedure was repeated 100 times
Figure 1. Clusterization of overt CD patients (open circles) and healthy controls (filled circles) obtained with kopls for cpmg serum
spectra (A), NOESY serum spectra (B), and NOESY urine spectra (C). Potential CD patients (triangles) are projected on the kopls
component, predicted by SVM, and filled or not accordingly to the results.
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inside a Monte Carlo cross-validation scheme. From this
procedure, we obtain unbiased generalization error estimation.
To avoid overtraining and to speed up the calculations, in the
inner loop of the cross-validation (parameter selection),
the SVM was kept with the default settings, varying only the
number of components and the kernel sigma parameter for
KOPLS.
To assess which buckets (that is, resonance peaks) were
significantly different between different groups, a univariate
wilcoxon test was used. A P-value e 0.05 was considered
statistically significant. The buckets whose values appeared to
be significantly different from the above statistical analysis were
manually checked to identify the associated resonance peak(s).
All resonances of interest were then manually checked and
signals were assigned on template one-dimensional NMR
profiles by using matching routines of AMIX 6.8 (Bruker
BioSpin) in combination with the BBIOREFCODE (Bruker
BioSpin) reference database and published literature when
available. All calculations were made using homemade scripts
written in R language.32 Serum citrulline concentrations in the
three groups were analyzed by two-way ANOVA, followed by
Tukey’s multiple comparison test, and a P-value of less than
0.05 was accepted to denote statistical significance.
Ethical Issue. The study was approved by the Internal Review
Board of the Department of Clinical Pathophysiology of the
University of Florence, and informed consent was obtained
from all patients and healthy volunteers.
Results
The clusterization of controls and overt untreated CD
patients for the three sets of experiments (serum CPMG, serum
NOESY, and urine NOESY) is shown in Figure 1. It appears that
the best clusterization is provided by the serum CPMG spectra.
The statistical models applied proved to be effective in
discriminating between patients and control subjects. These
results are in line with our previous work,14 where for the first
time the existence of a metabolic fingerprint of celiac disease
was demonstrated, both in serum and urine. Although the best
recognition accuracy is slightly less than previously reported
(81.2 vs 83.4 for serum CPMG spectra), these new data
undoubtedly confirm the existence of the metabolic signature
of CD, both in serum and in urine. In Table 1, the values for
classification accuracy for each experiment are reported.
If the potential CD patients are treated as blind samples and
are subjected to classification by the previous statistical model,
24 out of 29 are classified as CD patients using CPMG serum
spectra. Those results strongly suggest that potential CD
subjects are more similar to overt CD than to healthy controls.
Moreover, when the statistical analysis is used to discriminate
potential from overt CD patients, the accuracy is significantly
lower (57.8%). Furthermore, as shown in Table 2, this result is
highly asymmetric with high sensitivity (>70%) but poor
specificity (ca. 20%). Again potential CD subjects show a
behavior that is much more similar to overt CD.
When comparing spectra of serum samples of overt un-
treated CD patients and nonceliac controls, we find that CD
patients are characterized (P < 0.05) by lower levels of choline,
creatinine, isoleucine, lactate, leucine, methionine, valine,
lipids, and glycoproteins (from their N-acetyl signal) and higher
levels of glucose, citrate, serine, and phenylalanine.
In the case of urine, overt CD patients are characterized by
higher levels of acetoacetate, choline, glutamate/glutamine,
indoxyl sulfate (IS), meta-hydroxyphenyl-propioni acid (mH-
PPA), phenylacetylglycine (PAG), 3-hydroxybutyric acid, me-
thylamine, valeric acid, sarcosine, p-cresolsulfate, and 1-me-
thylnicotinamide. These data are summarized in Table 3. Even
though minor differences are present (due to the different data
set and slightly different statistical analysis), this pattern is
coherent with the previous work and corroborates the previous
findings.14
Comparing the serum spectra of overt CD with those of
potential CD, we find that potential CD patients are character-
ized by lower levels of dimethylglycine and higher levels of
glutamate and lipids (P < 0.05); no other metabolites are found
significantly different in serum. In urine, more differences are
found, in particular potential CD patients shows lower levels
of glutamate/glutamine, IS, mHPPA, PAG, p-cresolsulfate, and
citrate (see Table 3).
The metabolic differences between potential CD and non-
celiac controls in serum are quite similar to those between overt
CD and controls: potential CD subjects have lower levels of
creatinine, leucine, dimethylglycine, arginine, and lipids and
higher levels of glucose, proline, and glutamate. In urine,
potential CD subjects show lower levels of hippurate and higher
levels of dimethylamine, 1-methylnicotinamide, and citrate.
These data are summarized in Table 3.
Several of the potential CD patients analyzed here were put
on a GFD, although solely based on medical considerations
and not on the results frommetabolomics. At the present stage,
we have been able to examine again 13 of them, after an
average period of GFD of 6 months (Supporting Table S2): all
but three had negative TGA. By processing the follow-up serum
samples with the same statistical model built for the discrimi-
nation, we found that all of them, except for one of the three
positive to TGA, had reverted to a normal metabonomic profile.
In addition to metabolomic analysis, with the aim of obtain-
ing more information able to better characterize the clinical
Table 1. Cross-Validation Classification Results Obtained
Using CPMG and NOESY Serum Spectra and NOESY Urine
Spectra of Overt CD Patients and Nonceliac Controls (NC)
overt CD NC accuracy
Serum CPMG Spectra
overt CD 80.5% 19.5%
81.2%
NC 18.0% 82.0%
Serum NOESY Spectra
overt CD 77.4% 22.6%
75.5%
NC 26.7% 73.3%
Urine NOESY Spectra
overt CD 77.5% 22.5%
74.7%
NC 29.0% 71.0%
Table 2. Cross-Validation Classification Results Obtained
Using CPMG and NOESY Serum Spectra and NOESY Urine
Spectra of CD Patients and Potential CD Subjects
overt CD potential CD accuracy
Serum CPMG Spectra
overt CD 71.1% 28.9%
57.8%
potential CD 70.2% 29.8%
Serum NOESY Spectra
overt CD 67.6% 32.3%
55.2%
potential CD 71.1% 28.9%
Urine NOESY Spectra
overt CD 81.4% 18.6%
57.4%
potential CD 89.7% 10.3%
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phenotype of potential CD patients, we monitored and com-
pared the citrulline levels of the three kind of subjects (30 overt
CD, 51 controls, and 29 potential CD). Serum citrulline level is
in fact an indirect measure of the enterocyte mass and it was
proposed as a clinical biomarker for enterocyte dysfunctions
in many diseases.33-36 Although the idea of observing citrulline
levels of celiac patients is not new,37 this is, at the best of our
knowledge, the first time that such analysis is done in potential
CD patients. The results are extremely interesting because a
statistically significant difference (P < 0.001) is obtained not
only between CD patients and the control group (as expected),
but also between potential CD subjects and controls. Moreover,
the difference between CD patients and potential CD subjects
is not statistically significant (Figure 2).
Discussion
The present work classifies potential CD subjects (29) on the
basis of a learning set of controls and CD subjects that has been
considerably expanded with respect to the previous study14 (61
+ 51). The global accuracy obtained in discriminating nonceliac
control subjects and patients is good enough (81.2%) to allow
us to try to make predictions about the metabolic status of
potential CD subjects. It is important to stress here that in doing
so we are not proposing an alternative diagnostic test for the
screening of difficult cases, sometimes challenging also for
expert clinicians. Rather, this exercise is useful to have a
qualitative answer to the title question. Using CPMG serum
spectra, the result of the prediction is remarkably clear: out of
29 potential CD subjects, 24 are classified as CD and 5 are
classified as controls. Furthermore, three of the latter are
located near the cluster boundary (e.g., they are borderline
subjects) and only two are clearly classified as controls (Figure
1A). Although it is not possible to give a rationale for these
differences, the answer of metabolomics is straightforward:
potential CD subjects are extremely similar to overt CD
patients, at least in their metabolic profile.
If we build a statistical model optimized for the discrimina-
tion between celiac patients and potential subjects, the clas-
sification accuracy is very low: 57.8% for serum CPMG spectra,
55.1% for serum NOESY spectra, and 57.4% for urine. In all
cases, we have high sensitivity but a high rate of false discovery,
so the specificity is very poor (29%, 29%, and 10%). In other
words, it is impossible to separate overt CD from potential CD
subjects, based on metabolomics.
The analysis of the metabolic profiles reveals interestingly
similar behavior of overt CD and potential CD. Only few serum
metabolites differentiate potential from overt CD, and none of
these metabolites are relative to energy metabolism. In par-
ticular, it appears that, as in untreated CD patients, glycolysis
is somehow impaired. Impairment of glycolysis explains both
a lowering of lactate levels and an increase of glucose levels in
blood. This is confirmed by the metabolic pattern that dif-
ferentiates potential CD and nonceliac controls: most of the
significant metabolites are the same that differentiate overt CD
from control group.
In urine, there are many more metabolites that differentiate
potential CD from overt CD than from controls. Especially, the
key differences are in the metabolites originating from the gut
microflora (m-HPPA, IS, and PAG), suggesting a relationship
between overt CD, villous atrophy, and bacterial consortia of
the host. It is also reported38 that particular bacterial strains
may work in conjunction with gluten to cause an increased
immune response which is responsible of the development of
CD. A distinctive ‘microbial signature’ in celiac pediatric
patients is also reported.39
The similarity of the metabolic pattern in serum, and the
dissimilarity in urine, between overt and potential CD subjects
allow us to hypothesize that while the alterations in the urine
profile may follow intestinal damage, gluten intolerance exists
as such before an evident intestinal damage occurs.
Table 3. Metabolites Found To Be Statistically Different
(P < 0.05) in Sera (A) and Urine (B) of Untreated Overt CD
Patients, Potential CD Patients, and Nonceliac Controls (CD)a
metabolite
CD patients
vs NC
potential
CD vs NC
overt CD vs
potential CD
(A) Serum
Choline -
Creatinine - -
Glucose + +
Glycoproteins -
Isoleucine -
Lactate -
Leucine - -
Lipids - - -
Methionine -
Valine - -
Citrate +
Serine +
Phenilalanine +
Glutamate + + +
Dimethylglycine - +
Proline +
Arginine -
(B) Urine
Acetoacetate +
Choline +
Glutamate/Glutamine + +
Indoxyl Sulfate + +
mHPPA + +
PAG + +
3-OH-butirate +
Methylamine +
Valerate +
Sarcosine +
p-cresolsulfate +
1-methylnicotinammide + -
Citrate + - +
Hippurate -
a The + and - indicate, respectively, higher and lower levels of
metabolites concentrations in the first group of each classification, with
respect to the other.
Figure 2. Serum citrulline concentrations in the three groups of
subjects. In overt and potential CD, the mean serum citrulline
concentration was significantly lower (15.97 + 4.62 SD and 17.38
+ 3.70 SD) than in nonceliac controls (22.30 + 5.39 SD, *p
< 0.001). One-way analysis of variance followed by Tukey’s post
test was applied to the results.
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To clarify this aspect and to shed more light on the present
findings, we performed a serum citrulline assay. In humans,
citrulline is an amino acid involved in intermediary metabolism
and is not incorporated in proteins.40-42 Circulating citrulline
is mainly produced by enterocytes of the small bowel.43 For
this reason, plasma or serum citrulline concentration has been
proposed as a biomarker of residual small bowel mass and
function.44
Our data, in line with previous findings, clearly show that
citrulline levels in the CD patients are significantly lower than
in the control group. But, more strikingly, also potential CD
subjects, that from endoscopy do not show any manifest sign
of villous atrophy, have lower levels of citrulline than controls.
Indeed no statistically significant difference is found between
citrulline levels in CD patients and potential CD subjects
(Figure 2).
According to clinical experience, if a celiac subject has a
positive antibody test but does not show macroscopic alter-
ations of intestinal mucosa, there can be only two possibilities:
(1) a (limited) intestinal damage is present but the endoscopy
was not able to detect it (i.e., we admit some error in the
sampling procedure) or (2) the intestinal mucosa is really intact
and the subject is a so-called “potential CD subject”.
The interpretation of our data (both frommetabonomics and
from citrulline assay) suggests a third option: potential CD
subjects are, indeed, not potential at all. They already experi-
ence some subtle alteration of the enterocytes (at the micro-
scopic functional level but not at the macroscopic level) and
metabolically appear similar to overt CD also without any
histological evidence of intestinal damage. If this hypothesis
holds, the core result from our investigation would be that
metabolomics can detect CD also when its clinical manifesta-
tion is not fully evident. Moreover, these findings may bear the
important medical implication that the metabolic and entero-
cyte alterations of CD arise before macroscopic intestinal
damage and/or villous atrophy and precede the observable
modification of jejunal mucosa. In this context, the observation
that potential CD subjects are characterized by a similar serum
metabonomic fingerprint as overt CD patients provides a
further, more biological, rationale for the medical evidence-
based choice of putting potential CD subjects on a GFD.
Moreover, if the metabolic changes are (at least partially)
independent from the bowel malabsorption (i.e., metabolites
of gut microflora and energetic pathway), a deeper analysis of
this fingerprint can be helpful to infer more information on
the biochemistry of the development of the disease.
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